SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function.

Duan S, Zhang Q, Zhu J, Wang J

Organogenesis26 Jun 2025Cited by 5 (Europe PMC)

PMID40570323PMCIDPMC12258809DOI10.1080/15476278.2025.2519649PepBankPUB-40570323

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In aged human bone marrow mesenchymal stem cells, SS‑31 increased ATP production by 35%.
In plain wordsIn lab tests on aged human stem cells, SS‑31 raised ATP production by 35%.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseATP production
Study
humann: not reported in source
aged human BM-MSCs
Outcome group
Mitochondrial function · Aging and longevity
Studied dose
Dose not stated
Measurements
ATP production increase
35%
aged BM-MSCs
Source sentences
Summary
increasing ATP production by 35% and reducing ROS levels by 40% in aged BM-MSCs.
1 context sentence(design, population, supporting numbers)
Summary · context
This study delves into the rejuvenating effects of SS-31 on aged human Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), focusing on its potential to restore their diminished osteogenic differentiation capacity, a critical issue in geriatric medicine and bone tissue engineering.
Report a problemFND-4057032301
02LabIn vitro (cells)Efficacy outcome
In aged human bone marrow mesenchymal stem cells, SS‑31 reduced ROS levels by 40%.
In plain wordsIn lab tests on aged human stem cells, SS‑31 lowered reactive oxygen species by 40%.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseROS levels
Study
humann: not reported in source
aged human BM-MSCs
Outcome group
Mitochondrial function · Aging and longevity
Studied dose
Dose not stated
Measurements
ROS reduction
40%
aged BM-MSCs
Source sentences
Summary
reducing ROS levels by 40% in aged BM-MSCs.
1 context sentence(design, population, supporting numbers)
Summary · context
This study delves into the rejuvenating effects of SS-31 on aged human Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), focusing on its potential to restore their diminished osteogenic differentiation capacity, a critical issue in geriatric medicine and bone tissue engineering.
Report a problemFND-4057032302
03LabIn vitro (cells)Efficacy outcome
In aged human bone marrow mesenchymal stem cells, SS‑31 gave a 2.8-fold increase in ALP activity.
In plain wordsIn lab tests on aged human stem cells, SS‑31 raised a bone-forming enzyme marker 2.8-fold.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseALP activity
Study
humann: not reported in source
aged human BM-MSCs
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
ALP activity increase
2.8 fold
aged BM-MSCs
Source sentences
Summary
a 2.8-fold increase in ALP activity and a 3.5-fold increase in Alizarin Red S staining intensity.
1 context sentence(design, population, supporting numbers)
Summary · context
This study delves into the rejuvenating effects of SS-31 on aged human Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), focusing on its potential to restore their diminished osteogenic differentiation capacity, a critical issue in geriatric medicine and bone tissue engineering.
Report a problemFND-4057032303
04LabIn vitro (cells)Efficacy outcome
In aged human bone marrow mesenchymal stem cells, SS‑31 gave a 3.5-fold increase in Alizarin Red S staining intensity.
In plain wordsIn lab tests on aged human stem cells, SS‑31 raised mineral staining 3.5-fold, a sign of bone formation.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseAlizarin Red S staining intensity
Study
humann: not reported in source
aged human BM-MSCs
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Alizarin Red S intensity increase
3.5 fold
aged BM-MSCs
Source sentences
Summary
a 3.5-fold increase in Alizarin Red S staining intensity.
1 context sentence(design, population, supporting numbers)
Summary · context
This study delves into the rejuvenating effects of SS-31 on aged human Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), focusing on its potential to restore their diminished osteogenic differentiation capacity, a critical issue in geriatric medicine and bone tissue engineering.
Report a problemFND-4057032304
05LabIn vitro (cells)Mechanism
In aged human bone marrow mesenchymal stem cells, SS‑31 reduced NOS2 expression by 50%.
In plain wordsIn lab tests on aged human stem cells, SS‑31 lowered NOS2 gene activity by 50%.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseNOS2 expression
Study
humann: not reported in source
aged human BM-MSCs
Outcome group
Receptor activity and mechanism · Musculoskeletal
Studied dose
Dose not stated
Measurements
NOS2 expression reduction
50%
aged BM-MSCs
Source sentences
Summary
SS-31 reduced NOS2 expression by 50%, highlighting its therapeutic potential in age-related bone loss.
1 context sentence(design, population, supporting numbers)
Summary · context
This study delves into the rejuvenating effects of SS-31 on aged human Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), focusing on its potential to restore their diminished osteogenic differentiation capacity, a critical issue in geriatric medicine and bone tissue engineering.
Report a problemFND-4057032305
06LabIn vitro (cells)Efficacy outcome
In aged human bone marrow mesenchymal stem cells, SS‑31 enhanced oxygen consumption rates.
In plain wordsIn lab tests on aged human stem cells, SS‑31 raised oxygen consumption.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseOxygen consumption rate
Study
humann: not reported in source
aged human BM-MSCs
Outcome group
Mitochondrial function · Aging and longevity
Studied dose
Dose not stated
Source sentences
Summary
SS-31 intervention not only normalizes mitochondrial structure and function, reducing ROS levels and enhancing oxygen consumption rates
1 context sentence(design, population, supporting numbers)
Summary · context
This study delves into the rejuvenating effects of SS-31 on aged human Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), focusing on its potential to restore their diminished osteogenic differentiation capacity, a critical issue in geriatric medicine and bone tissue engineering.
Report a problemFND-4057032306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.